Hervé Eloi Dominique Brailly
Directeur Général chez INNATE PHARMA
Fortune : 2 M $ au 30/04/2024
Provenance du réseau au premier degré de Hervé Eloi Dominique Brailly
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 52 | |
17
| Private Company | Biotechnology | 17 |
École Nationale Supérieure des Mines de Paris
12
| College/University | Other Consumer Services | 12 |
Holding Company | Pharmaceuticals: Major | 12 | |
EuroBioMed
EuroBioMed Miscellaneous Commercial ServicesCommercial Services EuroBioMed engages as an association related to healthcare research, engineering innovation and support for companies and projects. It operates in the following business segments: teaching, fundamental, translational and clinical research, technological innovation centers, start-ups and, industrial success stories. The company was founded in 2009 and is headquartered in Marseille, France.
3
| Private Company | Miscellaneous Commercial Services | 3 |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.
2
| Non-Profit Organization | Miscellaneous Commercial Services | 2 |
Université d'Aix-Marseille
2
| College/University | Other Consumer Services | 2 |
Kalsiom SAS
Kalsiom SAS Pharmaceuticals: MajorHealth Technology Kalsiom SAS develops inflammatory auto-immunity disorders antibody therapy. The company was founded by Hervé Eloi Dominique Brailly and Olivier Mignen on April 20, 2020 and is headquartered in Brest, France.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Chambre de Commerce et d'Industrie Marseille Provence
Chambre de Commerce et d'Industrie Marseille Provence Other TransportationTransportation Chambre de Commerce et d'' Industrie Marseille Provence engages in the provision of financial information and trainings for business development. The company was founded on March 1, 1983 and is headquartered in Marseille, France.
1
| Private Company | Other Transportation | 1 |
BioCuster
1
| Private Company | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hervé Eloi Dominique Brailly via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Lyon | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
École des Hautes Études Commerciales de Paris | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree Masters Business Admin Masters Business Admin | |
INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Executive Officer Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
TRANSGENE | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Director of Finance/CFO Director/Board Member | |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst Private Equity Analyst Private Equity Analyst | |
Ecole Polytechnique | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact | |
ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
POXEL | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
SANOFI | Biotechnology | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
Centre National de la Recherche Scientifique
Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
ABIVAX | Pharmaceuticals: Other | Founder General Counsel Director/Board Member | |
ABLYNX | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
ESSEC Business School | College/University | Graduate Degree Masters Business Admin Undergraduate Degree | |
THERADIAG | Medical Specialties | Chief Executive Officer Chief Executive Officer Director/Board Member | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
TXCELL | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director/Board Member | |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
QIAGEN MARSEILLE | Miscellaneous Commercial Services | Founder Director of Finance/CFO | |
Transgene, Inc. | Director/Board Member Director/Board Member | ||
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | President Chief Executive Officer | |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
CARMAT | Medical Specialties | Founder Director/Board Member | |
Harvard Business School | College/University | Undergraduate Degree Graduate Degree | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
PHARNEXT SCA | Biotechnology | Founder Director/Board Member | |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
VEXIM | Medical Specialties | Founder Director/Board Member | |
Université des Sciences et Technologies de Lille | College/University | Graduate Degree Doctorate Degree | |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Medical Specialties | Chairman Director/Board Member | |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
GENEURO SA | Biotechnology | Director/Board Member Director/Board Member | |
AFFLUENT MEDICAL | Medical Specialties | Founder Chief Executive Officer | |
AMGEN INC. | Pharmaceuticals: Major | Investor Relations Contact Chief Tech/Sci/R&D Officer | |
Mckinsey & Co. SAS
Mckinsey & Co. SAS Miscellaneous Commercial ServicesCommercial Services Mckinsey & Co. SAS provides business and management consulting services. The company is headquartered in Paris, France. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Lafarge Canada, Inc.
Lafarge Canada, Inc. Construction MaterialsNon-Energy Minerals Lafarge Canada, Inc. engages in the provision of construction materials. It offers aggregates, asphalt, cement, concrete products, and ductal. The company was founded in 1956 and is headquartered in Calgary, Canada. | Construction Materials | Corporate Officer/Principal President |
Statistiques
Internationale
France | 37 |
Etats-Unis | 7 |
Royaume-Uni | 3 |
Belgique | 3 |
Danemark | 2 |
Sectorielle
Health Technology | 32 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 3 |
Government | 2 |
Opérationnelle
Director/Board Member | 548 |
Corporate Officer/Principal | 204 |
Chairman | 160 |
Chief Executive Officer | 97 |
Independent Dir/Board Member | 84 |
Relations les plus connectées
Insiders | |
---|---|
Anne-Sophie Herelle | 65 |
Patrick Sayer | 55 |
Philippe Pouletty | 51 |
Laurence Danon-Arnaud | 37 |
Célia Hart | 36 |
Jean-Daniel Henri Beurnier | 34 |
Tidjane Thiam | 30 |
Charles Woler | 29 |
Catherine Moukheibir | 29 |
Philippe Archinard | 24 |
Stéphane Boissel | 24 |
Olivier Andriès | 24 |
Philippe Boucheron | 24 |
Jean Deleage | 23 |
Patrick J. Langlois | 23 |
- Bourse
- Insiders
- Hervé Eloi Dominique Brailly
- Connexions Sociétés